MedTrace Logo

A Study of HRS-4729 Injection and HRS9531 Injection in Participants With Metabolic Dysfunction-Associated Steatohepatitis

NCT07660848 · Status: NOT_YET_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 160

Last updated 2026-06-22

No results posted yet for this study

Summary

The purpose of this study is to investigate the efficacy and safety of HRS-4729 injection and HRS9531 injection in adult participants with metabolic dysfunction-associated steatohepatitis after 52 weeks of treatment.

Conditions

  • Metabolic Dysfunction-Associated Steatohepatitis (MASH)

Interventions

DRUG

HRS-4729 Injection

HRS-4729 Injection; high dose, low dose

DRUG

HRS9531 Injection

HRS9531 Injection; high dose, low dose

DRUG

HRS-4729 Injection Placebo

HRS-4729 Injection Placebo

DRUG

HRS9531 Injection Placebo

HRS9531 Injection Placebo

Sponsors & Collaborators

  • Fujian Shengdi Pharmaceutical Co., Ltd.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-07-31
Primary Completion
2028-03-31
Completion
2028-07-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07660848 on ClinicalTrials.gov